SynthesisFrontiers in neurology2025
The diagnostic and prediction performance of MR diffusion kurtosis imaging in the glioma molecular classification: a systematic review and meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although diffusion magnetic resonance imaging (dMRI), particularly diffusion kurtosis imaging (DKI), has demonstrated efficacy in distinguishing between low- and high-grade gliomas, its predictive utility across various molecular genotypes remains unclear. Evaluating the accuracy of DKI and identifying sources of heterogeneity in its predictive performance could advance noninvasive molecular diagnostic methods and support the development of personalized treatment strategies. Materials and methods: A literature search of the PubMed, Web of Science, Cochrane Library, Embase, and Medline databases was performed. The studies retrieved were screened by two researchers (HFZ and ZGH), and those fulfilling the inclusion criteria were subsequently included in the meta-analysis. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. The analyses summarized the mean differences in mean kurtosis (MK) and mean diffusivity (MD) in patients harboring various genotypes using suitable models, and explored heterogeneity. Finally, a bivariate restricted maximum likelihood estimation method and meta-regression analysis were performed to assess diagnostic potential and stability. Results: Fourteen studies comprising 886 patients were included in this meta-analysis. Regarding MK and MD, the mean difference between isocitrate dehydrogenase ( Conclusion: MK and MD exhibited potential diagnostic utility in the prediction of glioma molecular status and should be explored in medical practice. These parameters should be compared with other MRI models to develop a stable and suitable genetic molecular prediction method for patients with gliomas. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024568923, CRD42024568923.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.